Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial

American Journal of Transplantation

Volumn 8, Issue 5, 2008, Pages 975-983

  Kliem, V ^a   Fricke, L ^b   Wollbrink, T ^b   Burg, M ^a   Radermacher, J ^c,d   Rohde, F ^e  

^a Lower Saxony Center for Nephrology   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d KLINIKUM MINDEN   (Germany)

^e ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

CMV; Ganciclovir; Graft survival; Preemptive therapy; Prophylaxis; Renal transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GRAFT SURVIVAL; HUMAN; INFECTION CONTROL; KIDNEY GRAFT; LEUKOPENIA; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; CREATININE; CYTOMEGALOVIRUS INFECTIONS; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; SAMPLE SIZE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 42149132743     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.02133.x     Document Type: Article

References (38)

1. Yang CW, Kim YO, Kim YS et al. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV sero-positive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. Am J Nephrol 1998 18 : 373 378.
2. Toupance O, Bouedjoro-Camus MC, Carquin J et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: A cohort study with case-control analyses. Transpl Int 2000 13 : 413 419.
3. Hokeberg I, Eriksson BM, Zweygberg-Wirgart B, Tufvesson G, Olding-Stenkvist E, Grillner L. Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients. Scand J Infect Dis 1995 27 : 435 440.
4. Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000 70 : 1166 1174.
5. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990 12 (Suppl 7 S754 S766.
6. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002 2 : 850 856.
7. Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004 66 : 329 337.
8. Green M, Avery RK, Preiksaitis J et al. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004 4 (Suppl 10 51 58.
9. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001 11 : 73 81.
10. Schnitzler MA, Lowell JA, Hmiel SP et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: The importance of HLA-DR matching. J Am Soc Nephrol 2003 14 : 780 785.
11. Bock GH, Sullivan EK, Miller D et al. Cytomegalovirus infections following renal transplantation-effects on antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997 11 : 665 671.
12. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004 4 : 928 936.
13. Humar A, Michaels M, AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 6 : 262 274.
14. EBPG (European Expert Group on Renal Transplantation), European Renal Association (ERA-EDTA), European Society for Organ Transplantation (ESOT). European best practice guidelines for renal transplantation (part 1). Nephrol Dial Transplant 2000 15 (Suppl 7 1 85.
15. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001 11 : 83 86.
16. Singh N. Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategies. J Clin Virol 2006 35 : 474 477.
17. Einsele H, Reusser P, Bornhauser M et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006 107 : 3002 3008.
18. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006 82 (2 Suppl S4 S8.
19. Pellegrin I, Garrigue I, Binquet C et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol 1999 37 : 3124 3132.
20. Von Muller L, Hampl W, Hinz J et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002 40 : 2285 2287.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 53 : 457 481.
22. Birk PE, Chavers BM. Does cytomegalovirus cause glomerular injury in renal allograft recipients? J Am Soc Nephrol 1997 8 : 1801 1808.
23. Boyce NW, Hayes K, Gee D et al. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 1988 45 : 706 709.
24. Soderberg-Naucler C, Emery VC. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 2001 71 (11 Suppl SS24 SS30.
25. Weissinger EM, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004 65 : 2426 2434.
26. Haubitz M, Wittke S, Weissinger EM et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005 67 : 2313 2320.
27. Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches. Electrophoresis 2005 26 : 1476 1487.
28. Mischak H, Apweiler R, Banks RE et al. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007 1 : 148 156.
29. Kliem V, Fricke L, Wollbrink T et al. In comparison to preemptive therapy general CMV prophylaxis with ganciclovir improves transplant survival significantly following renal transplantation [abstract]. Transplantationsmedizin 2006 18 (Suppl 2 127.
30. Strom TB. Rejection-more than the eye can see. N Engl J Med 2005 353 : 2394 2396.
31. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005 353 : 2342 2351.
32. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005 143 : 870 880.
33. Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Syst Rev 2006 1 : CD005133.
34. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005 365 : 2105 2115.
35. Lowance D, Neumayer HH, Legendre CM et al for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999 340 : 1462 1470.
36. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006 6 : 2134 2143.
37. Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 2007 21 : 149 158.
38. Freeman RB, Paya C, Pescovitz MD et al. Valganciclovir Solid Organ Transplant Study Group. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004 78 : 1765 1773.